Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively). It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.[1][2][3][4][5] Rivenprost has also been used to support wound healing.[6]

256382-08-8

C24H34O6S

450.59

ONO-4819;Rivenprost

DMF:30 mg/mL
Ethanol:30 mg/mL
DMSO:20 mg/Ml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years